Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

In this study, transethosomes were investigated as potential delivery systems for dimethyl fumarate. A formulative study was performed investigating the effect of the composition of transethosomes on the morphology and size of vesicles, as well as drug entrapment capacity, using cryogenic transmission electron microscopy, photon correlation spectroscopy, and HPLC. The stability of vesicles was evaluated, both for size increase and capability to control the drug degradation. Drug release kinetics and permeability profiles were evaluated in vitro using Franz cells, associated with different synthetic membranes. The in vitro viability, as well as the capacity to improve wound healing, were evaluated in human keratinocytes. Transmission electron microscopy enabled the evaluation of transethosome uptake and intracellular fate. Based on the obtained results, a transethosome gel was further formulated for the cutaneous application of dimethyl fumarate, the safety of which was evaluated in vivo with a patch test. It was found that the phosphatidylcholine concentration affected vesicle size and lamellarity, influencing the capacity to control dimethyl fumarate's chemical stability and release kinetics. Indeed, phosphatidylcholine 2.7% / led to multivesicular vesicles with 344 nm mean size, controlling the drug's chemical stability for at least 90 days. Conversely, phosphatidylcholine 0.9% / resulted in 130 nm sized unilamellar vesicles, which maintained 55% of the drug over 3 months. These latest kinds of transethosomes were able to improve wound healing in vitro and were easily internalised by keratinocytes. The selected transethosome gel, loading 25 mg/mL dimethyl fumarate, was not irritant after cutaneous application under occlusion, suggesting its possible suitability in the treatment of wounds caused by diabetes mellitus or peripheral vascular diseases.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9369351PMC
http://dx.doi.org/10.3390/ijms23158756DOI Listing

Publication Analysis

Top Keywords

dimethyl fumarate
12
formulative study
8
transmission electron
8
electron microscopy
8
release kinetics
8
improve wound
8
wound healing
8
transethosome gel
8
cutaneous application
8
chemical stability
8

Similar Publications

The NRF2/KEAP1 signaling pathway regulates the gene expression of numerous cytoprotective and detoxifying enzymes and is therefore essential for maintaining cellular redox homeostasis. Despite the increasing knowledge of NRF2 signaling complexity, dimethyl fumarate remains the sole NRF2-targeting therapy in clinical practice, used for multiple sclerosis. Ongoing research exploring the role of NRF2 in cancer, neurodegeneration, diabetes, and cardiovascular, renal, and liver diseases holds significant promise for future therapeutic innovation.

View Article and Find Full Text PDF

Dimethyl fumarate mitigates osteoarthritis progression through Nrf2 activation-mediated suppression of oxidative stress and subchondral osteoclastogenesis.

Int Immunopharmacol

September 2025

Department of Orthopaedics, The Second Affiliated Hospital and Yuying Childrens Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province, China; Key Laboratory of Orthopaedics of Zhejiang Province, Wenzhou, Zhejiang Province, China. Electronic address:

Osteoarthritis (OA) is a degenerative joint disease associated with imbalanced subchondral bone remodeling, and there is currently no curative treatment available. In OA, excessive osteoclast activity leads to bone loss and inflammatory responses. Dimethyl fumarate (DMF), an Nrf2 activator already used in treating psoriasis and multiple sclerosis, may alleviate OA by suppressing oxidative stress and osteoclastogenesis.

View Article and Find Full Text PDF

Target trial emulation to replicate randomised clinical trials using registry data in multiple sclerosis.

J Neurol Neurosurg Psychiatry

September 2025

Hospices Civils de Lyon, Service de Neurologie, sclérose en plaques, pathologies de la myéline et neuroinflammation, Bron, France.

Unlabelled: BackgroundTarget trial emulation (TTE) offers a formal framework for causal inference using observational data, but its validity must be evaluated in each research domain by replicating randomised clinical trials (RCTs). We aimed to replicate eight RCTs evaluating the efficacy of disease-modifying therapies (DMTs) in multiple sclerosis (MS) using French registry data.

Methods: This multicentre, retrospective, observational study was conducted using data extracted in December 2023 from the (OFSEP) database.

View Article and Find Full Text PDF

Dimethyl fumarate is an inhibitor of pathological angiogenesis.

Cell Signal

September 2025

School of Optometry and Vision Science, University of New South Wales, Kensington, NSW 2052, Australia. Electronic address:

Vascular endothelial growth factor (VEGF), a pro-angiogenic molecule, supports blood vessel growth during wound healing but also drives pathological neovascularization in blinding eye diseases such as neovascular age-related macular degeneration (nAMD). Dimethyl fumarate (DMFu), an FDA-approved drug for multiple sclerosis, has previously shown promising anti-inflammatory properties in retinal pigment epithelium, a crucial structure disrupted by nAMD. Here, we extend the multi-phenotypic therapeutic potential of DMFu by discerning the anti-angiogenic capabilities of DMFu in choroidal and retinal endothelial cells.

View Article and Find Full Text PDF

Background: Radiologically Isolated Syndrome (RIS) is defined as incidentally found MRI abnormalities that are radiographically indistinguishable from multiple sclerosis (MS) and is considered a presymptomatic disease state of MS. Age <37 years, infratentorial or spinal cord lesions, gadolinium-enhancing lesions on index imaging, and positive cerebrospinal fluid oligoclonal bands have been identified as risk factors for conversion to MS. There are no existing guidelines regarding the role of disease-modifying therapy (DMT) in RIS patients.

View Article and Find Full Text PDF